Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of FDA022-BB05 in advanced solid tumors
CTR20241323Phase 2Active
- Sponsor
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
- Start
- Jun 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of FDA022-BB05 in breast cancer, endometrial cancer (EC), transitional cell carcinoma (TCC), colorectal cancer (CRC), non-small cell lung cancer (NSCLC), sponsored by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.. Started Jun 2024; status: active.
02
Drugs
FDA022-BB05
03
Conditions
breast cancerendometrial cancer (EC)transitional cell carcinoma (TCC)colorectal cancer (CRC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20241323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241323.